A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Safety, Immunogenicity, and Dose Ranging Study of Purified Inactivated Zika Virus Vaccine (PIZV) Candidate in Flavivirus Naïve and Primed Healthy Adults Aged 18 to 49 Years
Phase of Trial: Phase I
Latest Information Update: 11 Dec 2017
At a glance
- Drugs TAK-426 (Primary)
- Indications Zika virus infection
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Takeda
- 28 Nov 2017 Status changed from not yet recruiting to recruiting, according to a Takeda Pharma media release.
- 28 Nov 2017 According to a Takeda Pharma media release, initial data are expected in 2018.
- 24 Nov 2017 New trial record